Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis

Clin Breast Cancer. 2010 Nov:10 Suppl 3:S59-65. doi: 10.3816/CBC.2010.s.013.

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway mediates multiple cellular functions critical to tumor initiation, progression, and outcomes, including growth and proliferation, metabolism, motility, migration, invasion, angiogenesis, survival, and autophagy. Tight regulation of this pathway is paramount to ensure that multiple cellular inputs are integrated for appropriate cellular outcomes. Frequent deregulation and aberrations of this pathway have been implicated in breast cancer development and progression. This review focuses on the biology of this pathway and its role in breast cancer pathogenesis. The role of therapies directed at targeting mTOR in the PI3K/Akt/mTOR pathway, which are currently being evaluated in clinical trials, will also be reviewed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / etiology
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Molecular Targeted Therapy / methods
  • Neoplasm Proteins / physiology*
  • Phosphatidylinositol 3-Kinase / physiology*
  • Proto-Oncogene Proteins c-akt / physiology*
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / physiology*

Substances

  • Antimetabolites, Antineoplastic
  • Neoplasm Proteins
  • MTOR protein, human
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases